The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures
Abstract
Summary: Purpose: To evaluate the efficacy and tolerability of levetiracetam (LEV, Keppra) as add‐on therapy in patients with refractory partial seizures. Methods: In this European multicenter, double‐blind, randomized, placebo‐controlled trial, LEV (500 or 1,000 mg twice daily) was compared with placebo as add‐on therapy in 324 patients with uncontrolled simple or complex partial seizures, or both, with or without secondary generalization. After enrollment, three parallel groups were assessed during a baseline period of 8 or 12 weeks, followed by a 4‐week titration interval and a 12‐week evaluation period. Results: LEV significantly decreased partial seizure frequency compared with placebo. A reduction in seizure frequency of 50% occurred in 22.8% of patients in the 1,000‐mg group and 31.6% of patients in the 2,000‐mg group, compared with 10.4% of patients in the placebo group. Administration of LEV did not affect plasma concentrations of concomitant an‐tiepileptic drugs or alter vital signs or laboratory parameters. No significant difference in the incidence of adverse events was observed between treatment groups (70.8% for the 1,000‐mg group and 75.5% for the 2,000‐mg group), or between the LEV and placebo groups (73.2% for placebo group). The most commonly reported adverse effects in the LEV group were asthenia, headache, and somnolence. Conclusions: The antiepileptic efficacy and tolerability of LEV (1,000 mg/d and 2,000 mg/d, administered in two divided doses) as add‐on therapy was established in patients with refractory partial seizures in this clinical study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Löscher, W., Hönack, D., & Rundfeldt, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 343
Löscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255
Gower, A. T., Hirsch, E., Boehrer, A., Noyer, M., & Marescaux, C. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00077-1 · Cited by 198
In Vitro Evaluation of Potential Drug Interactions With Levetiracetam, A New Antiepileptic Agent
Nicolas, J.-M., Collart, P., Gerin, B., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15285-3 · Cited by 109
Browne, T. R., Szabo, G. K., Leppik, I. E., Josephs, E., Paz, J., Baltes, E., & Jensen, C. M. (2000) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2000.tb05984.x · Cited by 56
Cited by
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
Trinka, E., Marson, A. G., Van Paesschen, W., Kälviäinen, R., Marovac, J., Duncan, B., Buyle, S., Hallström, Y., Hon, P., Muscas, G. C., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300376 · Cited by 121
Self-citationLevetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Wu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Metadata
- Authors
- Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2000-09
- Volume
- 41
- Issue
- 9
- Pages
- 1179-1186
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1979558709
- Cited by
- 451
- References
- 10
- FWCI
- 19.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures. https://app.cochat.ai/papers/10.1111/j.1528-1157.2000.tb00323.x
- The paper
- Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group. (2000). Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures. Epilepsia. https://doi.org/10.1111/j.1528-1157.2000.tb00323.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
